The Medicines Company

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

Phase 3

Completed

Conditions: Transcatheter Aortic Valve Replacement
Aortic Valve Replacement
Severe Aortic Stenosis

Interventions: Drug: Bivalirudin
Drug: Unfractionated Heparin

First Posted Date: 2012-07-27

Last Posted Date: 2017-04-07

Lead Sponsor: The Medicines Company

Target Recruit Count: 803

Registration Number: NCT01651780

Locations: 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada
🇨🇦
St. Paul´s Hospital Providence Health Care, Vancouver, Canada
🇫🇷
Centre Hospitalier de Lyon, Bron, France

and more 30 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery

Phase 2

Completed

Conditions: Coronary Artery Bypass Graft
Cardiopulmonary Bypass

Interventions: Drug: MDCO-2010
Drug: Placebo

First Posted Date: 2012-02-17

Last Posted Date: 2012-07-19

Lead Sponsor: The Medicines Company

Target Recruit Count: 32

Registration Number: NCT01535222

Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery

Phase 2

Terminated

Conditions: Bleeding

Interventions: Drug: MDCO 1
Drug: MDCO 2
Drug: MDCO 3
Drug: MDCO 4
Drug: Saline
Drug: Tranexamic Acid

First Posted Date: 2012-02-09

Last Posted Date: 2015-12-10

Lead Sponsor: The Medicines Company

Target Recruit Count: 44

Registration Number: NCT01530399

Locations: 🇩🇪
Charité Berlin, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn, Bonn, Germany
🇩🇪
Universität Leipzig - Herzzentrum, Leipzig, Germany

and more 2 locations

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Phase 3

Completed

Conditions: Percutaneous Coronary Intervention
Atherosclerosis
Acute Coronary Syndrome

Interventions: Drug: cangrelor P2Y12 (platelet) inhibitor
Drug: Clopidogrel - 300 or 600 mg (study arm)
Drug: Clopidogrel 600 mg post cangrelor

First Posted Date: 2010-07-05

Last Posted Date: 2014-02-04

Lead Sponsor: The Medicines Company

Target Recruit Count: 11145

Registration Number: NCT01156571

Locations: 🇺🇸
Anderson Area Medical Center, Anderson, South Carolina, United States

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2010-03-16

Last Posted Date: 2016-02-12

Lead Sponsor: The Medicines Company

Target Recruit Count: 2198

Registration Number: NCT01087723

Locations: 🇦🇹
Magistratsabeilung 70, Wiener, Wien, Austria
🇦🇹
Universitats-Klinik Fur, Wien, Austria
🇩🇰
Odense Universitets Hospital, Odense, Denmark

and more 142 locations

Utilisation of Angiox® in European Practice

Completed

Conditions: Stable Angina (SA)
NSTE-ACS (NSTEMI and UA)
STEMI (STE-ACS)

First Posted Date: 2009-11-11

Last Posted Date: 2012-01-19

Lead Sponsor: The Medicines Company

Target Recruit Count: 2019

Registration Number: NCT01011504

Locations: 🇫🇷
Centre Hospitalier Universitaire de Caen, Caen, France
🇩🇪
Medizinische Klinik I Kardiologie/Pneumologie/Internistische, Rostock, Germany

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

Phase 3

Completed

Conditions: Hypertension
Heart Failure

Interventions: Drug: Standard of Care IV antihypertensive
Drug: Clevidipine

First Posted Date: 2008-12-05

Last Posted Date: 2014-08-29

Lead Sponsor: The Medicines Company

Target Recruit Count: 117

Registration Number: NCT00803634

Locations: 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Jackson Hospital, Montgomery, Alabama, United States
🇺🇸
Louisiana State University Health Sciences Center, Baton Rouge, Louisiana, United States

and more 10 locations

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: clevidipine

First Posted Date: 2008-12-01

Last Posted Date: 2014-08-29

Lead Sponsor: The Medicines Company

Target Recruit Count: 30

Registration Number: NCT00799604

Locations: 🇺🇸
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Maintenance of Platelet Inhibition With Cangrelor

Phase 2

Completed

Conditions: Acute Coronary Syndrome (ACS)

Interventions: Drug: cangrelor
Other: Placebo

First Posted Date: 2008-10-07

Last Posted Date: 2014-04-04

Lead Sponsor: The Medicines Company

Target Recruit Count: 221

Registration Number: NCT00767507

Locations: 🇺🇸
Scripps Clinic / Scripps Green Hospital, La Jolla, California, United States

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Phase 4

Withdrawn

Conditions: Heparin-Induced Thrombocytopenia
Heparin-induced Thrombocytopenia and Thrombosis Syndrome

Interventions: Drug: bivalirudin

First Posted Date: 2008-09-25

Last Posted Date: 2020-10-19

Lead Sponsor: The Medicines Company

Registration Number: NCT00759083

Locations: 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy